<?xml version="1.0" encoding="UTF-8"?>
<p>Metabolic syndrome is composed of abnormal metabolism factors such as dyslipidemia, impaired glucose tolerance, insulin resistance, inflammation, obesity, and hypertension. Typically, metabolic syndrome is associated with many pathologies, especially type 2 diabetes mellitus, obesity, and cardiovascular diseases [
 <xref rid="B44" ref-type="bibr">44</xref>–
 <xref rid="B47" ref-type="bibr">47</xref>]. OA has potential protective effects on short-term and long-term metabolic dysfunction fructose-induced in rats [
 <xref rid="B48" ref-type="bibr">48</xref>]. And its mechanism of action may be related to hepatocyte nuclear factor 1b, an important regulator of glucose and lipid metabolism [
 <xref rid="B49" ref-type="bibr">49</xref>]. Many OA derivatives have therapeutic effects on metabolic diseases, such as patent CN 103739652A (
 <italic>α</italic>-glucosidase inhibitors), CN102838651A (OA derivatives as hypoglycemic agents), and CN1682740A (OA derivatives as glycogen phosphorylase inhibitors) [
 <xref rid="B50" ref-type="bibr">50</xref>].
</p>
